Psychedelic Drugs Could be the Answer


New research published in the Australian Psychologist Journal claims Australia is missing out on the benefits of using psychedelic drugs to treat a range of mental health illnesses.

The research, conducted by Edith Cowan University, Curtin University and Monash University says data gathered over the past 15 years has investigated the use of drugs including LSD, MDMA and psilocybin and the impact they have on people living with conditions such as post-traumatic stress, depression and anxiety.

However, misinformation and prejudice towards these types of drugs has halted psychedelic research in Australia, and other countries, meaning drug companies are hesitant to develop psychedelic treatments.

The study’s lead author Stephen Bright told Starts at 60 that Australia is falling behind when it comes to research on psychedelic treatments, noting a number of prestigious institutions including UCLA, John Hopkins School of Medicine and New York University have already conducted a series of clinical trials.

Click here to read the full article

Image: David Kovaluk

Share this post

Innovative psychedelic research

The re-emergence of psychedelic research places a crucial emphasis on a holistic approach to mental health from pharmacology, neurobiological process, ecological connection, and therapeutic support.  PRISM supports research and clinical development of therapies where current options provide limited relief.

Your support allows us to pursue cutting edge research for next-generation mental health care.


We are a DGR-1 non-profit research charity developing medical and legal processes for the application of psychedelic medicines for improved wellbeing.


Contact Us

Send us an email and we'll get back to you soon.

Not readable? Change text. captcha txt

Start typing and press Enter to search